Transaction DateRecipientSharesTypePriceValue
21st September 2020Advisors Llc Orbimed137,500Open or private sale$28.00$3,850,000.00
21st September 2020Capital Management, L.P. Ra2,145,045Conversion of derivative$0.00
21st September 2020Capital Management, L.P. Ra660,000Open or private purchase$19.00$12,540,000.00
17th September 2020Capital Management, L.P. Ra1,300,000Open or private purchase$28.00$36,400,000.00
15th September 2020Advisors Llc Orbimed902,885Grant/award etc.$0.00
15th September 2020Advisors Llc Orbimed4,822,960Grant/award etc.$0.00
15th September 2020Advisors Llc Orbimed292,607Grant/award etc.$0.00
9th September 2020Capital Management, L.P. Ra158,589Open or private sale$25.81$4,092,738.04
21st August 2020Capital Management, L.P. Ra2,129,003Conversion of derivative$0.00
18th August 2020Advisors Llc Orbimed43,543Open or private sale$108.54$4,726,157.22
Sc Pharmaceuticals
Sc Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


scPharmaceuticals, Inc. was founded by Pieter Muntendam and Bertram Pitt in February 2013. Its products include furosemide, used as parenteral diuretic in treating heart failure.


Ticker: SCPH
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1604950
Employees: 17
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals